Copyright © Inderes 2011 - present. All rights reserved.

Aiforia Technologies

1.86 EUR

-6.53 %

2,164 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

-6.53 %
-17.33 %
-25.30 %
-22.50 %
-44.14 %
-47.01 %
-56.39 %
-
-63.24 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
62.67M EUR
Turnover
114.64K EUR
P/E (adj.) (26e)
-7.51
EV/EBIT (adj.) (26e)
-7.76
P/B (26e)
4.64
EV/S (26e)
13.87
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
2026-03-08
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 2026-03-09

Latest extensive report

Released: 2025-04-24

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
2/4
2026

General meeting '26

28/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Is it okay to speculate? I watched the webcast, and one thing caught my eye and stayed with me. In the 2027 goals, “cash flow positivity” had changed to “financial independence,” and the CEO commented on this a bit. The point is that if the market really gains momentum now, as it...
3/7/2026, 9:06 PM
by JusaVaan
25
Here is a recent interview. Inderes Aiforia H2’25: Kasvua ja kaupallisia edistysaskeleita - Inderes Aika: 06.03.2026 klo 12.36 Aiforian H2-liikevaihto kasvoi vertailukaudesta 45 % ja ylitti ennusteemme selvästi. Kulusäästöt näkyivät käyttökatteessa, mutta kassan palamisvauhti on ...
3/6/2026, 11:21 AM
by Thiebault
22
Here is a new company report on Aiforia from Siltanen Aiforia’s H2 achieved higher revenue than we expected, and the result was in line with our forecast. Growth was generated in Europe, where the company has succeeded in advancing the adoption of clinical models. According to the...
18 hours ago
by Sijoittaja-alokas
17
Personally, I found the financial statement encouraging and raised my own target prices. The reason was that the scaling of the clinical business was promised to start in H2, and indeed it did. A significant, massive risk and concern has been removed. The market position is such ...
12 hours ago
by Puutaheinää
14
Nuways’ interim report update, target remains at €3.8 & Buy. Detailed reasoning behind the link. We make minor adjustments to our model. Given the strong performance of the Clinical segment in H2’25, our conviction in the long-term story remains intact. We thus reiterate our BUY ...
14 hours ago
by Opa
10
Unfortunately, the questions went unnoticed in the rush between the report and the webcast/interview. The intention is, of course, to always include questions. This is an angle that is raised quite often. Usually, companies’ response is something along the lines of: a directed issue...
3/6/2026, 1:19 PM
by Antti Siltanen
10
It looks like we’ll have time to get the H1/26 report out before the next offering is needed, so if growth in clinical use continues well (and why wouldn’t it), the share price probably won’t be this low, considering the potential offering. Will there be an Inderes interview with...
3/6/2026, 11:02 AM
by Puutaheinää
10
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.